Pharmacokinetic Analysis of the Bioavailability of AQUATURM®, a Water-Soluble Curcumin Formulation, in Comparison to a Conventional Curcumin Tablet, in Human Subjects

Background/Objectives: Curcumin, the principal bioactive component of Curcuma longa, is known for its anti-inflammatory, antioxidant, and neuroprotective properties. Despite its therapeutic potential, curcumin exhibits poor oral bioavailability due to low solubility, rapid metabolism, and limited ga...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Pharmaceuticals (Basel, Switzerland) Ročník 18; číslo 7; s. 1073
Hlavní autori: Jabur, Lillian, Pandey, Rishi, Mikhael, Meena, Niedermayer, Garry, Gyengesi, Erika, Mahns, David, Münch, Gerald
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: Switzerland MDPI AG 21.07.2025
MDPI
Predmet:
area under the curve
Bioavailability
Chemical properties
curcuminoids
Design
Dietary supplements
Drug dosages
Human subjects
Metabolism
Metabolites
Pharmaceutical research
Pharmacokinetics
Physiological aspects
Plasma
Purpura
Turmeric
water-soluble curcumin
Australia
water-soluble curcumin
pharmacokinetics
curcuminoids
area under the curve
plasma
bioavailability
ISSN:1424-8247, 1424-8247
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Background/Objectives: Curcumin, the principal bioactive component of Curcuma longa, is known for its anti-inflammatory, antioxidant, and neuroprotective properties. Despite its therapeutic potential, curcumin exhibits poor oral bioavailability due to low solubility, rapid metabolism, and limited gastrointestinal absorption. Various delivery systems have been developed to overcome these limitations. This study aimed to evaluate and compare the pharmacokinetic profile of AQUATURM®, a novel, water-soluble curcumin formulation, with that of a widely available commercial curcumin supplement. Methods: A randomized, double-blind, two-period crossover study was conducted in 12 healthy adult participants (6 male, 6 female; aged 20–45 years). Each participant received a single oral dose of either AQUATURM® or the comparator product, followed by a 7-day washout period before receiving the alternate treatment. Blood samples were collected at multiple time points over a 12-h period post-dosing. Plasma curcumin concentrations were quantified using ultra-performance liquid chromatography with tandem mass spectrometry (UPLC-MS/MS). Results: AQUATURM® achieved a significantly higher systemic exposure compared to the comparator, with a more than 7-fold increase in area under the curve (AUC0–12h) and higher peak plasma concentrations (Cmax). AQUATURM® also maintained detectable curcumin levels for the full 12-h observation period, whereas levels from the comparator fell below quantification limits in most participants after 4 h. Conclusions: AQUATURM® significantly enhances curcumin bioavailability in humans compared to a standard curcumin formulation. These pharmacokinetic improvements support its potential for greater clinical efficacy and warrant further evaluation in therapeutic setting
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1424-8247
1424-8247
DOI:10.3390/ph18071073